Edwin Christensen, MD
Family Medicine · Northport, ALNPI 1689635245
Payments from drug & device makers
Across 191 payments — averaging $16.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$658
- GSK$440
- Galderma Laboratories, L.p.$428
- Johnson & Johnson$233
- Novo Nordisk$218
- Astellas Pharma US Inc$165
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,14499%
- Education$381%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 48 | $658 |
| GSK | 30 | $440 |
| Galderma Laboratories, L.p. | 18 | $428 |
| Johnson & Johnson | 15 | $233 |
| Novo Nordisk | 13 | $218 |
| Astellas Pharma US Inc | 11 | $165 |
| Vifor Pharma, Inc. | 1 | $125 |
| Novartis | 8 | $123 |
| Exact Sciences | 6 | $112 |
| Boehringer Ingelheim | 3 | $75 |
| Pfizer | 5 | $70 |
| Lilly USA, LLC | 3 | $51 |
| Supernus Pharmaceuticals, Inc. | 2 | $40 |
| Amgen(2 entities) | 3 | $38 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Genentech USA, Inc. | 2 | $33 |
| Amarin Pharma, Inc. | 2 | $31 |
| AstraZeneca | 2 | $31 |
| Currax Pharmaceuticals LLC | 2 | $30 |
| Hikma Pharmaceuticals USA | 2 | $29 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Tolmar, Inc. | 1 | $22 |
| Abbott | 1 | $21 |
| Dexcom, Inc. | 1 | $20 |
| Gilead | 1 | $18 |
| Aytu Biopharma, Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Merck | 1 | $14 |
| Irhythm Technologies, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veltassa$125
How this compares
$3,183 in reported general payments places this provider in the 75th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 65 | $74,269 |
| EliquisApixaban | 45 | $61,367 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 79 | $54,968 |
| JardianceEmpagliflozin | 44 | $50,017 |
| FarxigaDapagliflozin Propanediol | 28 | $31,485 |
| MyrbetriqMirabegron | 24 | $30,159 |
| MounjaroTirzepatide | 24 | $26,592 |
| XareltoRivaroxaban | 13 | $23,071 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 24 | $21,876 |
| LinzessLinaclotide | 20 | $19,097 |
| Breo ElliptaFluticasone/Vilanterol | 40 | $17,298 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $15,197 |
| JanuviaSitagliptin Phosphate | 13 | $12,503 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 519 | $12,040 |
| Gabapentin | 355 | $6,230 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $218 | $74,26965 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $440 | $72,266119 claims |
| PfizerEliquis | $70 | $61,36745 claims |
| Boehringer IngelheimJardiance | $75 | $50,01744 claims |
| MerckJanumet Xr, Januvia | $14 | $34,37937 claims |
| AstraZenecaFarxiga | $31 | $31,48528 claims |
| Astellas Pharma US IncMyrbetriq | $165 | $30,15924 claims |
| Lilly USA, LLCMounjaro | $51 | $26,59224 claims |
| Johnson & JohnsonXarelto | $233 | $23,07113 claims |
| AbbVieLinzess, Synthroid | $658 | $21,97447 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Northport
- Clinton McEntyreNorthport$17K
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.